ReviewEuropean biophysics journal : EBJ2008
Neurotoxicity in Alzheimer's disease: is covalently crosslinked A beta responsible?
Review in European biophysics journal : EBJ, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 15 citations in OpenAlex.
- Structure-dependent effects of amyloid-β on long-term memory in Lymnaea stagnalis.FEBS letters · 2017Article
- Oxidized cholesterol as the driving force behind the development of Alzheimer's disease.Frontiers in aging neuroscience · 2015Review
- Interaction between amyloid-β pathology and cortical functional columnar organization.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2012Article
- Article
- Pharmacotherapeutic targets in Alzheimer's disease.Journal of cellular and molecular medicine · 2009Review
- The structure of the amyloid-beta peptide high-affinity copper II binding site in Alzheimer disease.Biophysical journal · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease is the most common form of dementia in the elderly, and is characterised by extracellular amyloid plaques composed of the beta-amyloid peptide (A beta). However, disease progression has been shown to correlate more closely with the level of soluble A beta oligomers. Recent evidence suggests that these oligomers are covalently crosslinked, possibly due to the interaction of A beta with redox-active metal ions. These findings offer new avenues for the treatment and prevention of disease, by modulating metal binding or preventing the formation of neurotoxic A beta oligomers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.